The population pharmacokinetics of amphotericin B colloidal dispersion in patients receiving bone marrow transplants

Chemotherapy

Volumn 45, Issue , 1999, Pages 48-53

  Amantea, Michael A ^a   Bowden, Raleigh A ^b   Forrest, Alan ^c   Working, Peter K ^a   Newman, Mary S ^a   Mamelok, Richard D ^a  

^a ALZA CORPORATION   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c Buffalo Clin Pharmacokin Lab   (United States)

Author keywords

Amphotericin B; Anti fungal agents; Bone marrow transplant; Colloidal dispersion; Pharmacokinetics

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; CREATININE;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; CLINICAL TRIAL; COMPARTMENT MODEL; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MYCOSIS; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; CREATININE; DEOXYCHOLIC ACID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FEMALE; FUNGEMIA; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; MYCOSES; TREATMENT OUTCOME;

EID: 0033062871     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000048470     Document Type: Article

References (19)

1. Kirsh R, Goldstein R, Tarloff J, Parris D, Hook J, Hanna N, Bugelski P, Poste G: An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis. J Infec Dis 1988; 158: 1065-1070.
2. Lopez-Berestein G, Fainstein V, Hopfer R: Liposomal amphotericin B for the treatment of systemic infections in patients with cancer: A preliminary study. J Infect Dis 1985;151:704-710.
3. Lopez-Berestein G, Bodey GP, Frankel LS, Mehta K: Treatment of hepatosplenic candidiasis with li-posomal-amphotericin B. J Clin Oncol 1987;5:310-317.
4. Shirkhoda A, Lopez-Berestein G, Holbert JM, Luna MA: Hepato-splenic fungal infection: CT and pathologic evaluation after treatment with liposomal amphotericin B. Radiology 1986; 159:349-353.
5. Forrest A, Hawtoff J, Egorin MJ: Evaluation of a new program for population PK/PD analysis: applied to simulated phase I data. Clin Pharmacol Ther 1991;49:153.
6. Forrest A, Ballow CH, Nix DE, Birmingham MC, Schentag JJ: Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrob Agents Chemother 1993;37: 1065-1072.
7. Prevost G: Estimation of a normal probability density function from samples measured with non-negligi-ble and non-constant dispersion. Internal Report. Palaiseau, Adersa-Gerbios, June 1977.
8. Racine-Poon A, Smith AFM: Population models; in Berry DA (ed): Statistical Methodology in the Pharmaceutical Sciences. New York, Dek-ker, 1990, p 139-162.
9. Stiemer JL, Mallet A, Golmard J, Boisieux J: Alternative approaches to estimation of population pharmacokinetic parameters: Comparison with the nonlinear mixed effect model. Drug Metab Review 1984; 15:265-292.
10. Sheiner LB: The population approach to pharmacokinetic data analysis: Rationale and standard data analysis methods. Drug Metab Rev 1984; 15:153-171.
11. D’Argenio DZ, Schumitzky A: A program package for simulation and parameter estimation in pharmacokinetic systems. Comp Programs Biomed 1979;9:15-134.
12. D’Argenio DZ, Schumitzky A: Adapt Users Guide. Biomedical Simulations Resource, University of California, Los Angeles, 1992.
13. Chiou WL, Hsu FH: Pharmacokinetics of creatinine in man and its implications in the monitoring of renal function and in dosage regimen modifications in patients with renal insufficiency. J Clin Pharm 1975; 45:427.
14. Wheeler LA, Sheiner LB: Clinical estimation of creatinine clearance. Am J Clin Path 1979;72:27.
15. Systat for Windows: Statistics, Version 5. Evanston, Systat, 1992.
16. Atkinson AJ, Bennett JE: Amphotericin B pharmacokinetics in humans. Antimicrob. Agents Che-mother 1978;13:271-276.
17. Fields BT, Bates JH, Abernathy RS: Effect of rapid intravenous infusion on serum concentrations of amphotericin B. Applied Microbiol 1971;2: 615-617.
18. Kan VL, Bennett JE, Amantea MA, Smolskis MC, McManus E, Grasela DM, Sherman JW: Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex and amphotericin B deoxycho-late in healthy male volunteers. J Infect Dis 1991;164:418-421.
19. Peterson LR, Kelty RH, Hall WH: Therapy of candida peritonitis; penetration of amphotericin B into peritoneal fluid. Postgrad Med J 1978; 54:340-342.